Same Indication

Lisdexamfetamine Dimesylate vs Nivolumab

Lisdexamfetamine Dimesylate vs Nivolumab: Overview

This comparison examines the pharmacological differences between Lisdexamfetamine Dimesylate and Nivolumab.

Mechanism of Action

Nivolumab: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

Pharmacokinetics

Half-life: Nivolumab β€” 27 days.

Chemical Properties

Type: Lisdexamfetamine Dimesylate β€” Small molecule; Nivolumab β€” Antibody.